BUZZ-墨西哥批准乳腺癌疫苗专利后，Anixa Biosciences 股价上涨

路透中文

Jan 27

BUZZ-墨西哥批准乳腺癌疫苗专利后，<a href="https://laohu8.com/S/ANIX">Anixa Biosciences</a> 股价上涨

1月27日 - ** 总部位于圣何塞的癌症治疗开发商 Anixa Biosciences ANIX.O 股价盘前上涨 7.47%，报 3.32 美元

** 该公司称 (link) 墨西哥工业产权局批准了其实验性乳腺癌疫苗的专利

** 该公司表示，这种疫苗旨在训练免疫系统，使其瞄准一种与肿瘤形成有关的蛋白质

** 该公司表示，墨西哥的专利是对美国和全球其他主要司法管辖区所颁发专利的补充，代表着未来在美国以外地区的监管和商业努力迈出了重要一步。

** 疫苗技术由美国医学研究中心克利夫兰诊所开发，并独家授权给 Anixa 公司使用。

** 2025 年股价上涨约 34%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2606278773"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606278773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606278773?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-01-27 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606278773","market":"us","top_or_hot":-1,"title":"BUZZ-墨西哥批准乳腺癌疫苗专利后，Anixa Biosciences 股价上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-墨西哥批准乳腺癌疫苗专利后，<a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> 股价上涨</title></head><body><p><span>1月27日</span><span> - </span>** 总部位于圣何塞的癌症治疗开发商 Anixa Biosciences <span>ANIX.O</span> 股价盘前上涨 7.47%，报 3.32 美元</p><p>** 该公司称 (link) 墨西哥工业产权局批准了其实验性乳腺癌疫苗的专利</p><p>** 该公司表示，这种疫苗旨在训练免疫系统，使其瞄准一种与肿瘤形成有关的蛋白质</p><p>** 该公司表示，墨西哥的专利是对美国和全球其他主要司法管辖区所颁发专利的补充，代表着未来在美国以外地区的监管和商业努力迈出了重要一步。</p><p>** 疫苗技术由美国医学研究中心克利夫兰诊所开发，并独家授权给 Anixa 公司使用。</p><p>** 2025 年股价上涨约 34%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-墨西哥批准乳腺癌疫苗专利后，Anixa Biosciences 股价上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-墨西哥批准乳腺癌疫苗专利后，Anixa Biosciences 股价上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-01-27 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-墨西哥批准乳腺癌疫苗专利后，<a href=\"https://laohu8.com/S/ANIX\">Anixa Biosciences</a> 股价上涨</title></head><body><p><span>1月27日</span><span> - </span>** 总部位于圣何塞的癌症治疗开发商 Anixa Biosciences <span>ANIX.O</span> 股价盘前上涨 7.47%，报 3.32 美元</p><p>** 该公司称 (link) 墨西哥工业产权局批准了其实验性乳腺癌疫苗的专利</p><p>** 该公司表示，这种疫苗旨在训练免疫系统，使其瞄准一种与肿瘤形成有关的蛋白质</p><p>** 该公司表示，墨西哥的专利是对美国和全球其他主要司法管辖区所颁发专利的补充，代表着未来在美国以外地区的监管和商业努力迈出了重要一步。</p><p>** 疫苗技术由美国医学研究中心克利夫兰诊所开发，并独家授权给 Anixa 公司使用。</p><p>** 2025 年股价上涨约 34%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIX","symbol_name":"Anixa Biosciences","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nL4T3YS1JA:1","article_id":"2606278773","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606278773","pubTimestamp":1769522544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ANIX":"Anixa Biosciences","BK4139":"生物科技"},"translate_title":"BUZZ-Anixa Biosciences shares jump after Mexico approves breast cancer vaccine patent","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIX":0.9},"content_text":"BUZZ-墨西哥批准乳腺癌疫苗专利后，Anixa Biosciences 股价上涨1月27日 - ** 总部位于圣何塞的癌症治疗开发商 Anixa Biosciences ANIX.O 股价盘前上涨 7.47%，报 3.32 美元** 该公司称 (link) 墨西哥工业产权局批准了其实验性乳腺癌疫苗的专利** 该公司表示，这种疫苗旨在训练免疫系统，使其瞄准一种与肿瘤形成有关的蛋白质** 该公司表示，墨西哥的专利是对美国和全球其他主要司法管辖区所颁发专利的补充，代表着未来在美国以外地区的监管和商业努力迈出了重要一步。** 疫苗技术由美国医学研究中心克利夫兰诊所开发，并独家授权给 Anixa 公司使用。** 2025 年股价上涨约 34%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}